Evidence map›Paper›PMID 40147096›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

DBeQ derivative targets vacuolar protein sorting 4 functions in cancer cells and suppresses tumor growth in mice.

Kevin A Fundora, Yan Zhuang, Kouta Hamamoto, Guifang Wang, Longgui Chen, Tatsuya Hattori, Xinwen Liang, Lei Bao, Venugopal Vangala, Fang Tian and 2 more

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kevin A FundoraDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Yan ZhuangDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Kouta HamamotoDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Guifang WangDepartment of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Longgui ChenDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Tatsuya HattoriDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Xinwen LiangDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Lei BaoDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Venugopal VangalaDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Fang TianDepartment of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Yoshinori TakahashiDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Electronic address: ytakahashi@pennstatehealth.psu.edu.
Hong-Gang WangDivision of Pediatric Hematology and Oncology, Department of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Electronic address: huw11@psu.edu.

Funding

Non-canonical Caspase-8 Activation on Autophagosomal MembranesR01CA222349 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HONG-GANG WANG · 2018 to 2026
$3.0M
Autophagosome closure by the ESCRT machineryR01GM127954 · NIGMS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI WANG, HONG-GANG · 2018 to 2025
$2.7M
NCI NIH HHS R01 CA222349NIGMS NIH HHS R01 GM127954
6 · The paper itself

Abstract

Vacuolar protein sorting 4 (VPS4) is an AAA-ATPase that catalyzes the endosomal sorting complex required for transport-III disassembly, mediating various cellular membrane-remodeling processes including endolysosomal membrane repair and autophagosome closure. Humans have 2 VPS4 paralogs, VPS4A and VPS4B, and the loss of either paralog has been identified in a significant proportion of cancers, rendering them dependent on the remaining paralog for survival. In this study, we explored VPS4 inhibition as an anticancer strategy by investigating the mechanisms of VPS4 inhibition-induced cell death and developing small-molecule compounds that target VPS4 functions. We found that genetic inhibition of VPS4 triggered both caspase-8 (CASP8)-dependent apoptosis and caspase-independent cell death in osteosarcoma cells. We synthesized approximately 100 derivatives of the VPS4 and related AAA-ATPase valosin-containing protein inhibitor DBeQ and screened for their inhibitory effects on VPS4 ATPase activity using the EnzChek phosphate assay and a high-content assay monitoring GFP-CHMP4B puncta formation. In cells, the lead compound 4-107 caused endolysosomal damage, disrupted subsequent membrane repair, inhibited autophagy, and led to the accumulation of the endosomal sorting complex required for transport on membranes. These effects were accompanied by the stabilization of CASP8 on autophagosomal membranes, leading to the induction of CASP8-mediated apoptosis. Notably, the CASP8-mediated cell death induced by 4-107 was further enhanced by the loss of either VPS4 paralog. Moreover, 4-107 exhibited antitumor activity in a syngeneic mouse model of neuroblastoma. Our findings provide an important step for targeting VPS4 in cancer and developing VPS4 inhibitors as a cancer treatment strategy. SIGNIFICANCE STATEMENT: VPS4A and VPS4B, paralogs of the AAA-ATPase VPS4, are critical for cancer cell survival. This study reports that 4-107, a DBeQ derivative, inhibits VPS4 ATPase activity, induces CASP8-mediated apoptosis, and suppresses tumor growth in mice. This study supports the further development of VPS4A/B inhibitors as a promising anticancer treatment strategy.

Indexed as

Antineoplastic AgentsEndosomal Sorting Complexes Required for TransportNeoplasmsAnimalsApoptosisATPases Associated with Diverse Cellular ActivitiesAutophagyCell Line, TumorCell ProliferationHumansMiceAntineoplastic AgentsATPases Associated with Diverse Cellular ActivitiesEndosomal Sorting Complexes Required for TransportApoptosisAutophagyESCRTLysosomal membrane integrityVPS4

Identifiers

PMID40147096
PMCPMC13095408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.